Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3493-3498

  Kato, Hiroyuki ^a   Fukuchi, Minoru ^a   Manda, Ryokuhei ^a   Nakajima, Masanobu ^a   Miyazaki, Tatsuya ^a   Sohda, Makoto ^a   Masuda, Norihiro ^a   Fukai, Yasuyuki ^a   Tsukada, Katsuhiko ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal carcinoma; Nedaplatin; Neoadjuvanttherapy

Indexed keywords

FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CARCINOMA; ESOPHAGUS METASTASIS; EVALUATION; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MEDICAL ASSESSMENT; MULTIPLE ORGAN FAILURE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 0042529167     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sugimachi K, Ohno S, Matsuda H et al: Clinicopathologic study of early stage esophageal carcinoma. Surgery 105: 706-10, 1989.
2. Kato H: Diagnosis and treatment of esophageal neoplasms. Jpn J Cancer Res 86: 993-1009, 1995.
3. McLean M, Brierley J and Casson AG. Oesophageal cancer: hope for the future. Clin Oncol 9: 1-3, 1997.
4. Ando N, Iizuka T, Kakegawa T et al: A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114: 205-209, 1997.
5. Fink U, Stein HJ, Bochtler H et al: Neoadjuvant therapy for squamous cell esophageal carcinoma. Ann Oncol 3: 17-26, 1994.
6. Raoul JL, Le Prise E, Meunier B et al: Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys 42: 29-34, 1998.
7. Kies MS, Rosen ST, Tsang TK et al: Cisplatin and 5- fluorouracil in the primary management of squamous esophageal cancer. Cancer 60: 2156-2160, 1987.
8. Hilgenberg AD, Carey RW, Wilkins EW Jr et al: Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45: 357-363, 1988.
9. Carey RW, Hilgenberg AD, Wilkins EW Jr et al: Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. Cancer Invest 11: 99-105, 1993.
10. Ajani JA, Ryan B, Rich TA et al: Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 28: 880-884, 1992.
11. Hosoya Y, Shibusawa H, Nagai H et al: Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect. Surg Today 29: 689-694, 1999.
12. Leichman L, Steiger Z, Seydel HG et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol 2: 75-79, 1984.
13. Poplin E, Fleming T, Leichman L et al: Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 5: 622-628, 1987.
14. Seydel HG, Leichman L, Byhardt R et al: Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG Study. Int J Radiat Oncol Biol Phys 14: 33-35, 1988.
15. Forastiere AA, Orringer MB, Perez-Tamayo C et al: Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 8: 119-127, 1990.
16. Hoff SJ, Stewart JR, Sawyers JL et al: Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. Ann Thorac Surg 56: 282-287, 1993.
17. Laterza E, Griso C, Urso US et al: Induction therapy for squamous carcinoma of thoracic esophagus. Ann Thorac Surg 57: 1126-1132, 1994.
18. Sasaki Y, Tamura T, Eguchi K et al: Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23: 243-246, 1989.
19. Suzumura Y, Kato T, Ueda R and Ota K: Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res 9: 1083-1088, 1989.
20. Sasaki Y, Fukuda M, Morita M et al: Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D).Jpn J Cancer Res 81: 196-200, 1990.
21. Fukuda M, Shinkai T, Eguchi K et al: Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26: 393-396, 1990.
22. Akaza H, Togashi M, Nishio Y et al: Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional- cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol 31: 187-192, 1992.
23. Adachi S, Ogasawara T, Wakimoto E et al: Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. Cancer 91: 74-79, 2001.
24. Yoshioka T, Gamoh M, Shineha R et al: A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med 38: 844-848, 1999.
25. Yamanaka H, Motohiro T, Michiura T et al: Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Jpn J Thorac Cardiovasc Surg 46: 943-948, 1998.
26. Japanese Society for Esophageal Diseases. Guidelines for the Clinical and Pathological Studies on Carcinoma of the Esophagus. The 9th edition. Tokyo: Kanehara; 1999.
27. Tobinai K, Kohno A, Shimada Y et al: Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257,1993.
28. Itoh Y, Fuwa N, Matsumoto A et al: Outcomes of radiotherapy for inoperable locally advanced (T4) esophageal cancer-retrospective analysis. Radiat Med 19: 231-235, 2001.
29. Tsujinaka T, Shiozaki H, Kido Y et al: Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery. J Surg Oncol 58: 50-56, 1995.
30. Coia LR, Engstrom PF, Paul AR et al: Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20: 29-36, 1991.
31. Seitz JF, Giovannini M, Padaut-Cesana J et al: Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer 66: 214-219, 1990.
32. Izquierdo MA, Marcuello E, Gomez de Segura G et al: Unresectable nonmetastatic squamous cell carcinoma of the esophagus managed by sequential chemotherapy (cisplatin and bleomycin) and radiation therapy. Cancer 71: 287-292, 1993.
33. Matsumoto Y, Ishiko O, Nakagawa E et al: Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin. Oncol Rep 8: 1269-1273, 2001.
34. Hsu CH, Yeh KH, Lui LT et al: Concurrent chemoradiotherapy for locally advanced esophageal cancera pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 19: 4463-4467, 1999.